A multicenter phase II study of Q3 week or weekly paclitaxel in combination with bevacizumab for the treatment of metastatic or unresectable angiosarcoma

Rare Tumors
Nam BuiKristen N Ganjoo

Abstract

Paclitaxel (P) and bevacizumab (B) are agents that provide clinical benefit in advanced angiosarcoma (AS). The objective of this study was to assess the efficacy and safety of P-B in two different scheduled regimens. Patients were to receive P 200mg/m2 IV with B 15mg/kg IV every 21 days (Regimen A) or P 90mg/m2 IV weekly D1, 8, 15 with B 15mg/kg IV D1 of a 28 day cycle (Regimen B) x6 cycles. Maintenance B followed at a dose of 15 mg/kg intravenously once every 21 days. The primary end point was 4 month non-progression rate (NPR). A total of 16 patients were enrolled. 4 month NPR was 62.5% with median overall survival 16 months and median progression free survival 5.06 months. 11 patients made it to cycle 3 and were evaluable for response with 1 CR (9%), 4 PR (36%), 2 SD (18%), and 6 PD (36%). There were ten grade 3 toxicities and four grade 4 toxicities. The breakdown between the two regimens revealed comparable efficacy and safety. Paclitaxel and Bevacizumab is an active regimen in angiosarcoma. Q3 week and weekly paclitaxel appear similar in efficacy and safety.

References

Oct 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·M A JordanL Wilson
Mar 17, 2004·Oncogene·Rajnish Bharadwaj, Hongtao Yu
May 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kirsten M LeuLaurence H Baker
Feb 26, 2005·The Breast Journal·John G WestJudith Harrison
Feb 24, 2006·International Journal of Cancer. Journal International Du Cancer·Jacques-Olivier BayUNKNOWN Groupe Sarcome Français
Nov 3, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J FayetteJ Y Blay
Sep 6, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M SchlemmerJ Y Blay
Sep 24, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicolas PenelJean-Yves Blay
Mar 24, 2009·Lancet·Ronald P DematteoUNKNOWN American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team
Sep 3, 2009·Cancer Research·Cristina R AntonescuRobert G Maki
Jan 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew J WagnerRobert G Maki
Dec 31, 2010·Annals of Diagnostic Pathology·Jorge Albores-SaavedraFredy Chablé-Montero
Jul 13, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C F VerschraegenT Bocklage
Aug 23, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M AgulnikR S Benjamin
Aug 29, 2012·International Journal of Cancer. Journal International Du Cancer·Mark A DicksonIzabela A Malinowska
Mar 13, 2014·The Lancet Oncology·Ian JudsonUNKNOWN European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
Mar 19, 2014·Nature Genetics·Sam BehjatiPeter J Campbell
Dec 30, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Paul F RobbinsSteven A Rosenberg
Jul 29, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Isabelle L Ray-CoquardNicolas Penel
Jul 30, 2015·The New England Journal of Medicine·William D TapGideon Bollag
Sep 16, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George D DemetriShreyaskumar R Patel
Nov 4, 2015·Cancer Research·Naoki ShimozonoHironobu Ihn
Sep 14, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christopher W RyanPatrick Schöffski
Mar 1, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C F VerschraegenT Bocklage

❮ Previous
Next ❯

Citations

Aug 21, 2019·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·N BönischP Terheyden
Jan 25, 2019·Current Treatment Options in Oncology·Megan Meyer, Mahesh Seetharam

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01055028

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.